Vapreotide
A somatostatin analogue for bleeding varices that never reached US approval
Vapreotide is a somatostatin analogue developed at Tulane University and licensed to Debiopharm. In a phase 3 trial in patients with cirrhosis and bleeding oesophageal varices, starting it early, before endoscopy, improved control of bleeding and survival over five days. It has no FDA approval.
Used in human trials: 50 µg bolus, then 50 µg/h, Continuous infusion, Intravenous (Trial: acute variceal bleeding in cirrhosis, before endoscopy) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Bleeding from oesophageal varices is a life-threatening complication of portal hypertension in cirrhosis, and recommended treatment includes giving a vasoactive drug early. Vapreotide is a somatostatin analogue with a different receptor affinity from octreotide; in rats with cirrhosis it lowered portal pressure and blood flow in collateral vessels, and it is much more metabolically stable than somatostatin itself.
Its pivotal trial gave a 50 µg intravenous bolus and then 50 µg an hour for five days, starting a mean of 2.3 hours after admission, before endoscopic treatment. At endoscopy, active bleeding was seen in 31% on vapreotide against 46% on placebo, and survival with control of bleeding over five days was 66% against 50%. Reviews also describe a meta-analysis of four randomised studies showing better bleeding control, and a mortality reduction in the subset with significant bleeding.
Like other somatostatin analogues, it was tried in cancer. In men with prostate cancer that had escaped hormone therapy, a few responded, some for years; in metastatic breast cancer, it lowered IGF-1 but no tumour shrank. As a radiolabelled imaging agent it offered nothing over octreotide. Laboratory work found an unexpected second action, blocking the NK1 receptor for substance P.
Other uses held up less well: a placebo-controlled trial in pancreatic surgery found no benefit, and the AIDS-diarrhoea data are uncontrolled. In volunteers, a week of infusion sharply reduced gallbladder emptying. Despite the variceal results, an openFDA search finds no US approval.
Mechanism of Action
Vapreotide is a synthetic octapeptide somatostatin analogue, more stable than somatostatin, with a receptor affinity different from octreotide's.
Portal pressure
In cirrhotic rats it lowered portal pressure and collateral blood flow without systemic effects.
Somatostatin-like inhibition
Lowered IGF-1 in women with breast cancer and sharply reduced gallbladder emptying in volunteers; its rise in stomach pH faded within a week.
NK1 receptor
Also blocks substance P at the NK1 receptor in human cells, reducing inflammatory signalling.
Published Research
Studies of vapreotide, from their PubMed abstracts.
Early vapreotide for variceal bleeding
In 196 patients with cirrhosis, active bleeding at endoscopy was 31% on vapreotide against 46% on placebo (P = 0.03), and survival with bleeding control over 5 days was 66% against 50% (P = 0.02).
No benefit after pancreatectomy
In a double-blind trial of 275 patients having elective pancreatic resection, pancreas-related complications occurred in 30.4% on vapreotide and 26.4% on placebo, and other complications in 40% and 42%; neither difference was significant.
Gut effects in healthy volunteers
In a crossover trial in 10 healthy men, a week of continuous vapreotide (1.5 mg a day under the skin) cut meal-stimulated gallbladder ejection to 18-20% against 57-62% on placebo; its rise in gastric pH faded from day 2 to day 7, and gastrin did not change.
Refractory AIDS-related diarrhoea
In an open pilot study of 34 patients, 4 of 30 evaluable had a complete and 12 a partial response (stool output down by more than half) at 14 days; those without cryptosporidiosis responded more often (P = 0.013), and 5 of 8 responders relapsed.
Prostate cancer at relapse
In 13 men whose prostate cancer had escaped androgen ablation, vapreotide gave 2 complete and 4 partial responses by ECOG criteria, with only transient mild diarrhoea; three remained in remission beyond three years.
Metastatic breast cancer: no responses
In 14 women given high-dose continuous infusion, IGF-1 fell and raised prolactin normalised, but no tumour responded and all progressed within three months; abscesses formed at the infusion site in eight.
As an imaging agent
In four patients, indium-labelled vapreotide found the same lesions as labelled octreotide but cleared more slowly, giving higher background, and added nothing for scintigraphy.
The evidence base
Vapreotide, with a receptor affinity different from octreotide's, lowered portal pressure in cirrhotic rats; its pivotal trial improved bleeding control, with lower mortality in significant bleeding, and a meta-analysis of four trials improved bleeding control.
Benefit and side effects
Vapreotide appeared to help control acute variceal bleeding, was easy to give and had few, minor side effects; the authors called for further trials.
Drug profile
Vapreotide (Octastatin, Sanvar, RC 160, BMY 41606), developed at Tulane University and licensed to Debiopharm, is far more metabolically stable than somatostatin and is usually given subcutaneously, with slow-release forms in development.
Development programme
Debiopharm was running phase 3 trials of vapreotide in prostate cancer in France and in acute oesophageal variceal bleeding in France and Asia, and investigating acromegaly.
Collateral blood flow in cirrhotic rats
A single dose lowered collateral (splenorenal shunt) blood flow by 17% and portal pressure by 8% without systemic effects; chronic dosing slowed the development of collateral flow.
A second target: the NK1 receptor
In human cells, vapreotide blocked substance P signalling through the NK1 receptor, reduced inflammatory cytokine release and inhibited HIV-1 infection of macrophages.
Dosing Data
There is no approved dose. The variceal bleeding trial gave a 50 µg intravenous bolus, then 50 µg an hour for five days.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Vapreotide is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
An arithmetic example, not a recommendation: a 5 mg vial mixed with 2 mL of bacteriostatic water holds 2,500 mcg per mL, so every 10 units on a U-100 insulin syringe hold 250 mcg. 1.5 mg, the first amount in the “Trial: healthy volunteers” row (1.5 mg a day) is 60.0 units (0.600 mL). If your vial or water differ, the numbers change: use the reconstitution calculator.
Source: dose: Used in human trials, PMID 10190655 (Dosing Data below); vial and water: the calculator's default example, not a vial size we have a source for.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Vapreotide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Vapreotide stays intact once mixed.
How it is taken
As it was given in human studies: Intravenous (Continuous infusion; Trial: acute variceal bleeding in cirrhosis, before endoscopy); Subcutaneous (Continuous infusion; Trial: healthy volunteers).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: acute variceal bleeding in cirrhosis, before endoscopy: 5 days; Trial: healthy volunteers: 1 week.
When effects appear: unknown; no source on this page gives a time to effect for Vapreotide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Few side effects, usually minor; Reduced gallbladder emptying during a week of continuous infusion. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Vapreotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Vapreotide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Vapreotide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (No FDA approval: an openFDA Drugs@FDA search for vapreotide returned no records (October 3, 2026)). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No US label; it is not approved in the US.
Legal Status
Vapreotide is not approved in the US. Its phase 3 programme in variceal bleeding did not lead to a US approval.
Frequently Asked Questions
?What is vapreotide?
A somatostatin analogue, related to octreotide, developed mainly for acute bleeding from oesophageal varices in cirrhosis.
?Did it work?
In its pivotal trial, survival with control of bleeding over five days was 66% on vapreotide against 50% on placebo when started before endoscopy.
?Is vapreotide approved in the US?
No. An openFDA search of Drugs@FDA finds no approval.
?How is it different from octreotide?
Reviews describe it as having a different somatostatin receptor affinity from octreotide; both lower portal pressure, and octreotide is approved in the US for other uses.
?How was it given in the bleeding trial?
As an intravenous bolus followed by an infusion of 50 micrograms per hour for five days, started a mean of 2.3 hours after admission, with endoscopic treatment a mean of 2.6 hours after the infusion began.
?Was it tested for other conditions?
Yes. Debiopharm ran phase 3 trials in prostate cancer in France and investigated acromegaly, and slow-release intramuscular and other sustained-release forms were developed.
?Can I buy vapreotide?
It has no FDA approval, so anything sold under its name in the US is an unverified research chemical rather than a licensed medicine.
?Did it work against cancer?
Only occasionally. In 13 men with prostate cancer that had escaped hormone therapy, six responded, some for over three years. In 14 women with metastatic breast cancer, no tumour responded despite lower IGF-1, and infusion-site abscesses were common.
?What side effects were seen?
Few in the bleeding studies, which reviews describe as minor. In volunteers it cut gallbladder emptying from about 60% to under 20%, and in the breast cancer trial continuous infusion under the skin caused abscesses in eight of 14 women and a small rise in blood glucose.
References
- [fda] US FDA, Drugs@FDA via openFDA: search for generic name vapreotide returned no records. Read October 3, 2026.
- [clinical-trial] Calès P, et al. "Early administration of vapreotide for variceal bleeding in patients with cirrhosis." N Engl J Med, 2001;344(1):23-8. PMID: 11136956.
- [pubmed] Calès P. "Vapreotide acetate for the treatment of esophageal variceal bleeding." Expert Rev Gastroenterol Hepatol, 2008;2(2):185-92. PMID: 19072353.
- [pubmed] Fortune BE, et al. "Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding." Expert Opin Pharmacother, 2009;10(14):2337-42. PMID: 19708854.
- [pubmed] "Vapreotide: BMY 41606, RC 160, Sanvar." Drugs R D, 2003;4(5):326-30. PMID: 12952505.
- [pubmed] Norman P. "Vapreotide (Debipharm)." IDrugs, 2000;3(11):1358-72. PMID: 16047258.
- [clinical-trial] Sarr MG. "The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial." J Am Coll Surg, 2003;196(4):556-64; discussion 564-5; author reply 565. PMID: 12691930.
- [clinical-trial] Ritz MA, et al. "The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects." Br J Clin Pharmacol, 1999;47(2):195-201. PMID: 10190655.
- [clinical-trial] Girard PM, et al. "Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases." AIDS, 1992;6(7):715-8. PMID: 1354449.
- [pubmed] González-Barcena D, et al. "Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse." Prostate, 2003;56(3):183-91. PMID: 12772187.
- [pubmed] O'Byrne KJ, et al. "Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer." Br J Cancer, 1999;79(9-10):1413-8. PMID: 10188884.
- [pubmed] Breeman WA, et al. "Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide." Eur J Nucl Med, 1998;25(2):182-6. PMID: 9473268.
- [pubmed] Veal N, et al. "Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis." Dig Dis Sci, 2003;48(1):154-61. PMID: 12645803.
- [pubmed] Spitsin S, et al. "Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor." Neuroimmunomodulation, 2013;20(5):247-55. PMID: 23921645.
Sources & Citations
Studies were read from their PubMed abstracts; no label exists. Read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.